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INTRODUCTION
Pulmonary complications occurring after hematopoietic
cell transplantation are a major cause of morbidity and mor-
tality [1]. When associated with diffuse lung injury in the
absence of an identiﬁable infection, it has been recommended
that these complications be referred to as idiopathic pneumo-
nia syndrome (IPS) [2]. IPS comprises a diverse group of clin-
ical presentations and is likely multifactorial in etiology. After
allogeneic transplantation, IPS occurs at an incidence of 10%
to 15%, with onset a median of 21 days posttransplantation,
and is associated with a high mortality of nearly 75% [3]. IPS
after autologous hematopoietic cell transplantation is more
heterogeneous. The expression of the disease can be disparate
depending on the primary disease and the nature of the
preparative regimen, and severity and risk of fatality are more
variable than after allogeneic transplantation.
Of particular interest is a milder form of pulmonary
injury that follows high-dose chemotherapy (HDC) and
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ABSTRACT
We performed a retrospective review to investigate pulmonary toxicity syndrome (PTS) in a cohort of breast cancer
patients undergoing BCNU-containing high-dose chemotherapy (HDC). Our aim was to characterize presentation,
identify risk factors, determine outcome following therapy, and find any association with differences in survival. We
reviewed the data of 152 patients with stage II or III or metastatic breast cancer treated with cyclophosphamide
5625 mg/m2, cisplatin 165 mg/m2, and BCNU 600 mg/m2 followed by autologous peripheral blood hematopoietic cell
transplantation. During follow-up, PTS was diagnosed when the following criteria were met: (1) presentation with
typical clinical symptoms of PTS, (2) an absolute carbon monoxide diffusion capacity (DLCO) decline of 10% com-
pared with pre-HDC DLCO, and (3) no clinical evidence of active pulmonary infection. Patients were then treated
with a course of corticosteroid therapy. The incidence of PTS for all 152 patients was 59%, with a median onset at
45 days (range, 21-149 days) post-HDC. The median absolute DLCO decrement was 26% (range, 10%-73%) at
diagnosis of PTS. There was no significant correlation between patient age, stage of breast cancer, pre-HDC chemo-
therapy regimen, pre-HDC chest wall radiotherapy, tobacco use, prior lung disease, or baseline pulmonary function
test results and the development of PTS. We did observe an interesting association between PTS and the develop-
ment of a noncholestatic elevation of transaminases. Of PTS patients treated with prednisone therapy for a median of
105.5 days (range, 44-300 days), 91% achieved resolution of their PTS without pulmonary sequelae. At 3 years, the
overall survival (OS) of stage II or III patients who developed PTS was 84% (95% confidence interval [CI], 73%-
95%); of metastatic breast cancer patients with PTS, the OS was 58% (95% CI, 38%-78%). These values were not
significantly different from those of patients who did not develop PTS (91% [95% confidence interval [CI], 81%-
100%] and 53% [95% CI, 32%-74%], respectively). No significant differences in disease-free or event-free survival
were observed between patients with and without PTS. The incidence of PTS in breast cancer patients treated with a
BCNU-containing HDC regimen can be remarkably high. Treatment with a course of corticosteroid therapy is suc-
cessful in the vast majority.
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autologous transplantation for breast cancer patients treated
with carmustine (BCNU)-containing preparative regimens
[4-8]. If left untreated, this syndrome is often progressive
and may be lethal. The syndrome of drug-induced interstitial
pneumonitis is frequently referred to as pulmonary toxicity
syndrome (PTS). The incidence of PTS from BCNU-
containing regimens is well described and, as reported by
several small series [4-8], ranges from 29% to a remarkably
high 64%. Potential risk factors included older age, prior
chest radiotherapy, and higher levels of systemic BCNU
exposure, although not all studies reported concordant ﬁnd-
ings. In contrast, clinical presentation with respect to symp-
toms was consistent and characteristically included cough,
dyspnea, and fever with or without diffuse (usually intersti-
tial) pulmonary inﬁltrates on radiographic examination. The
median time of onset was modestly delayed at approximately
50 days posttransplantation but well within the period rec-
ognized for the potential development of pulmonary com-
plications. The major objective ﬁnding was a decline in the
pulmonary diffusing capacity as assessed by pulmonary func-
tion testing (PFT). This constellation of symptoms, circum-
stances, and radiographic/PFT ﬁndings reliably predicted a
good response to a brief course of corticosteroid therapy,
even in the absence of invasive diagnostic procedures for
exclusion of active pulmonary infections [9,10]. Conse-
quently, the occurrence of PTS contributed little to the
observed transplantation-related mortality in those series.
The benefits of HDC with autologous hematopoietic
cell rescue will continue to be closely scrutinized as interim
results from large randomized trials become available.
Signiﬁcant numbers of patients have undergone the procedure
at many transplant centers [11,12], according an important
opportunity to study many aspects of autologous transplan-
tation, including issues related to complications and toxici-
ties, particularly in light of the transplantation-related
mortality rate reported in the recent intergroup trial [43]
using high dose cyclophosphamide, cisplatin, and BCNU
for high-risk breast cancer patients.
In this study, we describe the results of our retrospective
analyses of 152 patients with high-risk and metastatic breast
cancer uniformly treated with a BCNU-containing prepara-
tive regimen at a single institution. Using a larger patient
cohort than has been previously reported for this well-
recognized and significant problem, we aimed to examine
the incidence of PTS, characterize its presentation,
investigate potential risk factors, determine its response to
corticosteroid therapy, and ﬁnd out if it was associated with
differences in survival.
PATIENTS AND METHODS
Patients
A computerized database query was used to identify
180 consecutive breast cancer patients who had undergone
HDC and autologous peripheral blood hematopoietic cell
transplantation between February 26, 1995, and June 23,
1999, at the Stanford University Medical Center. A mini-
mum posttransplantation observation period of 8 weeks was
required. Twenty-eight patients participated in a prospective
randomized study evaluating the efficacy of amifostine in
PTS prevention and thus were excluded from this analysis.
A retrospective chart review was performed for the remain-
ing 152 patients. The median follow-up at the time of this
analysis was 29 months (range, 1-56 months). All patients
were treated after giving written informed consent under a
research protocol approved by the Stanford University
Medical Center Administrative Panel on Medical Human
Subjects. Patients having histologically proven, resected
breast cancer in stage II (10 or more involved nodes) or
stage III disease or metastatic breast cancer (MBC) were eli-
gible for treatment under this protocol. Additional eligibil-
ity criteria included the following: more than 3 weeks since
last chemotherapy, Karnofsky performance status ≥80%,
minimum life expectancy of at least 6 months, radiographic
absence of brain metastases, and PFT demonstrating single-
breath carbon monoxide diffusion capacity (DLCO), forced
expiratory volume (FEV1), and forced vital capacity (FVC)
all >60% of predicted values.
Baseline patient characteristics including pre-HDC
chemotherapy, pre-HDC radiotherapy, tobacco use, prior
lung disease, and cytomegalovirus (CMV) immune status
were recorded.
HDC and Autologous Hematopoietic Cell
Transplantation
Before chemotherapy, peripheral blood hematopoietic
cells were collected from each patient after G-CSF adminis-
tration. All patients were uniformly treated with a preparative
regimen consisting of cyclophosphamide 5625 mg/m2, cis-
platin 165 mg/m2, and BCNU 600 mg/m2 according to the
STAMP I protocol [13]. After HDC, the unmanipulated
autologous peripheral blood hematopoietic cells were
reinfused on day 0 as described [14]. Post-HDC supportive
care was delivered according to standard institutional practice.
In addition to HDC, 107 patients underwent post-
transplantation radiotherapy for consolidation. Of those
patients, 104 with advanced local-regional disease received
standard radiotherapy to the chest wall and ipsilateral
draining lymph nodes at a minimum dose of 5040 cGy,
generally initiated 6 weeks after transplant unless delayed
by cytopenias or pulmonary toxicity. Three patients with
bone metastases received consolidative involved field irra-
diation to sites of initial involvement (vertebral spine in
2 patients, ribs in 1 patient).
PTS Evaluation and Treatment During Follow-Up
All patients were closely followed at the Stanford Uni-
versity Medical Center with at least weekly chest radio-
graphic and physical examinations until 60 days posttrans-
plantation. PFTs were not scheduled preemptively but were
performed upon the development of symptoms or the ﬁnd-
ing of signs indicating pulmonary toxicity. Spirometry and
DLCO, corrected for the measured hemoglobin value,
were performed according to standard guidelines of the
American Thoracic Society [15,16]. All FEV1, FVC, and
DLCO measurements are expressed as percentages of the
predicted value. PFT data from all patients were available
for analysis.
A diagnosis of PTS required that all the following cri-
teria, which were standardized by the group of clinical
investigators, be met: (1) typical symptoms such as non-
productive cough, dyspnea, and fever or a chest radiograph
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demonstrating diffuse abnormalities; (2) an absolute
decline in DLCO of 10% from pre-HDC baseline levels;
and (3) no clinical evidence of active pulmonary infection.
Because of the high incidence of noninfectious pulmonary
toxicity in this setting as observed by our own group and
others, invasive fiber optic bronchoscopy or lung biopsy
was rarely required to establish the diagnosis of PTS
[5,17]. Diagnostic bronchoscopy with bronchoalveolar
lavage was performed in 2 patients, 1 of whom also under-
went transbronchial lung biopsy, after infections were
excluded by culture and cytology.
Patients diagnosed with PTS were treated with pred-
nisone at an initial dose of 1 mg/kg per day for 1 to 2 weeks,
followed by a gradual taper over 8 weeks depending on
response. Consolidative radiotherapy, when indicated, was
delayed until prednisone was tapered to 10 mg/day and then
completed with maintenance corticosteroid therapy at that
dose. All patients received Pneumocystis carinii pneumonia
prophylaxis of daily double-strength trimethroprim/sul-
famethoxasole or aerosolized pentamidine.
The timing of PTS onset, clinical presenting features,
duration of prednisone therapy, incidences of exacerbation
by post-HDC radiotherapy, and clinical outcome were
recorded. Because of the association between BCNU expo-
sure and hepatotoxicity, liver function test (LFT) data at
baseline and post-HDC were collected [18]. Post-HDC
LFT data were recorded at the time of PTS diagnosis or at
day 60 if the patient did not develop PTS.
A patient with PTS was considered to have resolved dis-
ease without sequelae if prednisone had been successfully
tapered off and no symptoms of pulmonary compromise
were present, without a requirement for follow-up PFT
evaluation. Residual pulmonary deficits were defined as a
documented DLCO of 10% below baseline after ≥180 days
of prednisone therapy.
Statistical Analysis
Comparison of the clinical characteristics between
patients with and without PTS was performed with the
Wilcoxon rank sum test in the case of median age and LFT
values, the Fisher exact test for proportions in the case of
categorical data, and the Student t test for the means of
PFT values [19]. The Kaplan-Meier method was used to
estimate the distribution of survival, and differences
between the 2 groups were assessed with the log rank test
[20]. Overall survival (OS), disease-free survival (DFS), and
event-free survival (EFS) were assessed separately. OS was
defined as time from HDC to death from any cause or
until the most recent follow-up for patients who were still
alive. DFS and EFS times were defined as time from HDC
to relapse, death from any cause, or until the most recent
follow-up if neither of those events had occurred. DFS
estimations differ from EFS in that nonrelapse deaths were
censored at time of death.
RESULTS
Patient Characteristics
The characteristics of all 152 patients are summarized
in Table 1. There were 92 stage II or III patients and
60 MBC patients. The median age was 46 years (range, 21
to 65 years). Before HDC, nearly all patients had received
doxorubicin and cyclophosphamide in chemotherapy regi-
mens given as adjuvant or primary therapy for metastatic
disease. A smaller number of patients had also been treated
with paclitaxel, docetaxel, or methotrexate. With the excep-
tion of doxorubicin, all of these agents have been associated
with diffuse lung injury [21-23]. With respect to additional
potential risk factors for PTS, 30 patients (20%) had
undergone radiotherapy to the chest wall; 18 patients
(12%) had a history of tobacco use (median 13.5 pack-years
[range, 2-30 pack-years]), 6 of whom were active smokers at
the time of registration for HDC; all 7 patients (5%) with
prior lung disease had a history of asthma; and 98 patients
(65%) were seropositive for CMV.
Clinical Features of Patients With PTS
The clinical features of the 90 patients (59%) who
developed PTS are summarized in Table 2. The median
onset was at 45 days posttransplantation (range, 21 to
149 days). Of stage II or III patients, 57 developed PTS, as did
33 MBC patients (the difference was not signiﬁcant [P = .41]).
Only 3 patients (3%) were diagnosed with PTS after pre-
senting solely with an abnormal chest radiograph; thus
almost all patients had symptomatic disease at presentation.
The median absolute decline in DLCO was 26% of the pre-
dicted value (range, 10%-73%), representing a 28% reduc-
tion from the median pre-HDC baseline DLCO.
No pre-HDC variable was found to be signiﬁcantly dif-
ferent between the patients with and without PTS (Table 3).
Variables assessed included cancer stage, median age at
HDC, and mean FEV1, FVC, and DLCO values measured
at baseline. We also assessed the number of patients in each
group with respect to chemotherapy received before HDC,
Table 1. Patient Characteristics*
Breast cancer patients 152
With stage II/III disease 92
With metastatic disease 60
Age, y 46 (21-65)
Sex, M/F 1/151
Pre-HDC chemotherapy
Doxorubicin-containing 145
Cyclophosphamide-containing 149
Taxane-containing 41
Methotrexate-containing 30
Pre-HDC chest wall radiotherapy 30
History of tobacco use 18
Pack-years 13.5 (2-30)
History of lung disease 7
Cytomegalovirus seropositive† 98
Baseline pulmonary function test
FEV1, % of predicted 102.6 ± 17.4
FVC, % of predicted 101.7 ± 16.9
FEV1/FVC ratio 80.4 ± 7.7
DLCO, % of predicted 93.2 ± 16.8
*Data are n, median (range), or mean ± SD. DLCO indicates carbon
monoxide diffusion capacity; FEV1, forced expiratory volume; FVC,
forced vital capacity; HDC, high-dose chemotherapy.
†Immunoglobulin G antibody.
T.M. Cao et al.
390
pre-HDC chest wall radiotherapy, prior tobacco use, history
of lung disease, and CMV immune status.
Transient Transaminitis Associated With PTS
A noncholestatic transaminitis characterized by an eleva-
tion of alanine aminotransferase (ALT) was found signiﬁcantly
more frequently in patients with PTS (Table 4). The median
ALT at the time of PTS diagnosis was 67 mU/mL; the day 60
value for patients without PTS was 36.5 mU/mL (P < .0001).
This difference was also evident in that 47 patients (52%) with
PTS had an ALT value greater than or equal to twice their pre-
HDC values; this abnormality was found in only 6 patients
(10%) who did not develop PTS (P < .0001).
Outcome of Patients With PTS
Upon diagnosis of PTS, all 90 patients were promptly
initiated on oral prednisone therapy at a starting dose of
1 mg/kg per day (Table 5). The prednisone was tapered over
the ensuing 8 to 10 weeks depending on response, except in
the case of patients who received post-HDC consolidative
radiotherapy. To prevent exacerbation of PTS during and
after radiotherapy, their dose was tapered to 10 mg/day and
maintained while they underwent irradiation. The median
duration of prednisone therapy was 105.5 days (range, 44-
300 days); there was a significant difference in treatment
duration between patients who received radiotherapy and
those who did not. Patients given radiotherapy required a
median of 111.5 days (range, 55-300 days) of prednisone
therapy, and patients who were not irradiated required a
median of 67 days (range, 44-281 days) (P < .002). After start-
ing radiotherapy, 5 patients (8%) had an exacerbation of PTS
necessitating an increase in the prednisone dose. There were
no occurrences of steroid-induced hyperglycemia requiring
therapy. Eight patients (9%) developed dermatomal zoster.
All patients received sulfa or pentamadine prophylaxis, and
there were no cases of Pneumocystis carinii pneumonia.
The development of PTS had no signiﬁcant impact on
OS, DFS, or EFS at a median follow-up of 29 months
(range, 1-56 months) (Table 6). In 82 patients (91%), pred-
nisone was successfully tapered off and the PTS resolved
without sequelae. Five patients (6%) developed residual pul-
monary deficits with persistent symptoms and DLCO
abnormalities observed at follow-up PFT. Three patients
(3%) died, either with PTS as the cause of death or with
unresolved PTS at the time of death. For stage II or III
patients, the estimated OS at 3 years for patients with PTS
was 84% (95% confidence interval [CI], 73%-95%) com-
pared with 91% (95% CI, 81%-100%) for patients without
PTS (P = .89). There was no signiﬁcant difference (P = .84)
in estimated 3-year OS between MBC patients with and
without PTS (58% [95% CI, 38%-78%] and 53% [95% CI,
32%-74%], respectively). Likewise, no difference in DFS
was observed for stage II or III patients (P = .22) or MBC
patients (P = .46) with or without PTS. Kaplan-Meier
curves for OS, DFS, and EFS are shown in the Figure.
DISCUSSION
Pulmonary edema, diffuse alveolar hemorrhage, and
infections from a myriad of pathogens are among the possi-
ble pulmonary complications after hematopoietic cell trans-
plantation [1,24]. An additional pulmonary complication
associated with diffuse lung injury in the absence of a deﬁn-
able infection was the topic of a recent National Heart,
Lung, and Blood Institute (NHLBI) workshop and was
given the designation IPS [2]. In the autologous setting, a
milder form of IPS attributed to chemotherapy drug toxic-
ity, PTS, is increasingly recognized as an important compli-
cation because of an incidence that can be remarkably high.
Using a set of diagnostic criteria meant to be compatible
with recent NHLBI guidelines for establishing the diagnosis
of PTS, we analyzed a relatively large cohort of breast can-
cer patients treated with a BCNU-containing preparative
regimen and HDC. The incidence of PTS, as defined by
Table 2. Characteristics of Patients With Pulmonary Toxicity Syndrome
(PTS)*
Breast cancer patients with PTS 90 (59)
With stage II/III disease 92 (57)
With metastatic disease 60 (33)
Onset, d posttransplantation 45 (21-149)
Presentation
Symptomatic only 65
Abnormal chest radiograph only 3
Symptomatic and abnormal chest radiograph 22
Pulmonary function test at diagnosis of PTS
FEV1, % predicted 89.7 ± 18.7
FVC, % predicted 84.9 ± 16.7
FEV1/FVC ratio 82.7 ± 8.6
DLCO, % predicted 63.8 ± 12.0
Absolute DLCO decrement, % 26 (10-73)
*Data are n (%), n, median (range), or mean ± SD. FVC indicates
forced vital capacity; FEV1, forced expiratory volume; DLCO, carbon
monoxide diffusion capacity.
Table 3. Comparison of Patients With and Without Pulmonary Toxicity
Syndrome (PTS)*
With PTS Without PTS P
n 90 62
Age, y 45.5 (21-65) 47 (31-61) .19
Pre-HDC chemotherapy
Doxorubicin-containing 87 58 .44
Cyclophosphamide-containing 88 61 .99
Taxane-containing 28 13 .20
Methotrexate-containing 17 13 .84
Pre-HDC chest wall radiotherapy 18 12 .99
History of tobacco use 11 7 .99
History of lung disease 5 2 .70
Baseline pulmonary function test
FEV1, % predicted 101.6 ± 15.6 104.1 ± 19.1 .39
FVC, % predicted 100.7 ± 15.1 103.2 ± 18.5 .38
FEV1/FVC 80.4 ± 6.4 80.3 ± 9.3 .94
DLCO, % predicted 93.4 ± 16.6 93.2 ± 17.0 .94
Cytomegalovirus seropositive† 58 40 .99
*Data are n, median (range), or mean ± SD. FVC indicates forced vital
capacity; FEV1, forced expiratory volume; DLCO, carbon monoxide dif-
fusion capacity.
†Immunoglobulin G antibody.
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(1) demonstration of diffuse lung injury (abnormal physiol-
ogy as evidenced by decrements in the DLCO) and (2)
absence of active pulmonary infections on clinical grounds,
was found to be 59%. This high incidence rate makes PTS
the most common complication observed during the noncy-
topenic early posttransplantation period for this cohort.
We did not require bronchoalveolar lavage or lung biopsy
to exclude an active infectious process and establish a diagno-
sis of PTS, based on our early experience with initial ﬁber
optic bronchoscopy and lung biopsy. Several other groups
have validated similar noninvasive approaches for evaluating
pulmonary symptoms in the posttransplantation period after
BCNU-based HDC. At the medical center of the University
of California, Los Angeles, 64 breast cancer patients were
prospectively followed. When presenting with symptoms sug-
gestive of BCNU-associated PTS, each patient was assigned a
clinical score based on physical examination, DLCO value,
2-minute exercise oximetry, and chest radiography [25]. All
37 patients identiﬁed as having lung toxicity were successfully
treated with a brief course of corticosteroid therapy. At the
Duke University Medical Center, investigators performed a
retrospective analysis of 45 breast cancer patients who were
rigorously screened with scheduled PFT assessments after
HDC and autologous transplantation [9]. A decline in DLCO
was observed in 64% of the patient population, and it signiﬁ-
cantly correlated with the onset of pulmonary symptoms. In
all affected patients, the DLCO subsequently improved fol-
lowing a course of corticosteroid therapy.
In the autologous setting, graft-versus-host disease is
absent, and in PTS, by definition, pulmonary infection is
absent; thus the cause of PTS is likely related to the toxicity
of the preparative regimen. As 1 of 3 drugs used in this regi-
men, BCNU can be reasonably implicated as the causative
agent, although cyclophosphamide has also been associated
with lung injury. The available data supporting cyclophos-
phamide as a drug with pulmonary toxicity consists largely
of case reports; no large clinical studies characterizing an
association with lung injury have been published [26-28]. In
addition, non-BCNU HDC regimens containing cyclo-
phosphamide have been associated with rare incidences of
pulmonary toxicity [29,30]. The literature is more convinc-
ing in support of BCNU as a consistent and dose-related
cause of pulmonary injury. In the nontransplantation set-
ting, up to 30% of patients with malignant gliomas treated
for an extended period with BCNU to a cumulative dose
range of 700 to 1800 mg/m2 developed pulmonary ﬁbrosis,
with a profound increase in incidence observed when the
dose exceeded 1500 mg/m2 [31]. In a dose-finding study
evaluating an HDC regimen of cyclophosphamide, etopo-
side, and BCNU, the incidence of pulmonary toxicity was
5% with a BCNU dose of 450 mg/m2 and 28% with a dose
of 600 mg/m2 [32]. Furthermore, it is possible that the dose
and scheduling of BCNU relative to cyclophosphamide in
the STAMP I regimen may account for the higher severity
and incidence of PTS in our patients.
It has been noted that high plasma levels of transforming
growth factor (TGF)-β in the pretransplantation setting cor-
relate with the subsequent development of PTS [33,34].
TGF-β is a 25-kd homodimeric protein that transduces its
signal via the Smad proteins, is known to stimulate collagen
production, and has been associated with a number of ﬁbro-
genic conditions including experimental drug–induced PTS
[35-37]. Although these ﬁndings suggest that certain patients
may have a predisposition to developing PTS with HDC, our
attempt to identify risk factors by examining a number of pre-
transplantation variables failed to reveal any signiﬁcant corre-
lations. Preexisting lung disease (as reﬂected by differences in
baseline pulmonary function or prior tobacco use) did not
correlate with the development of PTS. However, the num-
ber of patients who had prior lung disease or were former or
active smokers was low; therefore, the power to establish sig-
niﬁcance was limited. Prior chest wall radiotherapy, which
had been demonstrated to be a predictor of lung toxicity in
Table 4. Liver Function Tests in Patients With and Without Pulmonary
Toxicity Syndrome (PTS)*
With PTS Without PTS P
n 90 62
Baseline
Alkaline phosphatase, mU/mL 80.5 (39-264) 79 (46-200) .43
ALT, mU/mL 31 (15-85) 31.5 (9-90) .46
Total bilirubin, mg/dL 0.5 (0.3-1.1) 0.5 (0.2-1.1) .11
After high-dose chemotherapy
Alkaline phosphatase, mU/mL 73 (33-206) 76 (34-303) .80
ALT, mU/mL 67 (18-389) 36.5 (17-187) <.0001
Total bilirubin, mg/dL 0.6 (0.3-1.7) 0.6 (0.1-1.4) .29
ALT elevation ≥2 times baseline 47 6 <.0001
*Data are median (range) or n. ALT indicates alanine aminotransferase;
HDC, high-dose chemotherapy.
Table 5. Prednisone Therapy and Clinical Outcome*
Duration of prednisone therapy, d
All PTS patients (n = 90) 105.5 (44-300)
Post-HDC radiotherapy (n = 65) 67 (44-281)
No post-HDC radiotherapy (n = 25) 111.5 (51-300)†
Clinical outcome
Resolved without sequelae 82 (91)
With residual pulmonary deficits 5 (5)
With fatal PTS or active PTS at death 3 (3)
*Data are median (range) or n (%). PTS indicates pulmonary toxicity
syndrome; HDC, high-dose chemotherapy.
†P < .002 versus patients with post-HDC radiotherapy.
Table 6. Survival*
Overall Disease-Free Event-Free
Breast cancer patients
Stage II/III
With PTS 84 (73-95) 81 (70-92) 76 (64-88)
Without PTS 91 (81-100) 66 (48-84) 66 (48-84)
Metastatic disease
With PTS 58 (38-78) 24 (6-42) 22 (5-39)
Without PTS 53 (32-74) 33 (13-53) 32 (12-52)
*Data are % (95% conﬁdence interval). PTS indicates pulmonary toxi-
city syndrome.
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Overall survival (OS) (A), disease-free survival (DFS) (B), and event-free survival (EFS) (C) according to disease stage and presence of pulmonary
toxicity syndrome (PTS).
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patients subsequently treated with HDC [30], failed to corre-
late with the development of PTS in the current study. Again,
the limited number of patients who received prior radiother-
apy precluded meaningful assessment of correlation in our
patient population. Whereas the retrospective nature of this
study may make hazardous the formulation of deﬁnitive con-
clusions, our data suggest that readily identiﬁable clinical fea-
tures are not likely to predict the development of PTS in a
patient undergoing a BCNU-based HDC regimen.
We did find a highly significant correlation between
PTS and the concurrent development of transient non-
cholestatic transaminitis. Approximately half of the patients
who developed PTS also presented with a greater than 2-fold
elevation of ALT. The association of transaminitis and PTS
appears plausible, given that BCNU is a known hepatotoxin
[18]. Furthermore, marked inhibition of glutathione reduc-
tase by BCNU in both lung and liver, resulting in diminished
levels of reduced glutathione (which ordinarily protects
against free radical injury) in the cytosol, has been demon-
strated in rats and cultured cell lines [38-40]. BCNU may
cause tissue injury by impairing this important antioxidant
defense mechanism; in animal models, the impairment per-
sists for approximately 8 days after BCNU exposure [41]. It
is conceivable that by this mechanism, subclinical liver and
lung injury occurs in the immediate posttransplantation
period following high-dose BCNU exposure, but how this
process predisposes the patient to delayed symptomatic
expression remains unclear. Given that PTS responds to
corticosteroid therapy, it is possible that the spectrum of
PTS is a manifestation of both the injury and its elicitation
of an inﬂammatory response.
Although this was not a prospective trial designed to
formally address the efﬁcacy of corticosteroids in the treat-
ment of PTS, our data and those of others demonstrate suc-
cessful treatment of PTS following BCNU-based HDC in
the vast majority of patients [9,10,42]. Furthermore, in this
report, we show that a diagnosis of PTS had no signiﬁcant
effect on OS, DFS, or EFS in the cohort of patients strati-
ﬁed by disease stage.
A sobering finding, however, is the nearly 10% of
patients with PTS who were observed to have persistent
residual pulmonary deﬁcits or whose death (3 patients [3%])
was at least in part attributable to PTS. This ﬁnding serves
to emphasize the need for development of treatment regi-
mens that result in less pulmonary toxicity, administration of
early preemptive low-dose corticosteroids to all patients,
new methods to prevent lung injury, or perhaps improved
methods of recognizing the disease earlier when treatment
may be more successful.
Among the large randomized trials of HDC in high-risk
primary and metastatic breast cancer, the US intergroup trial
reported by Peters et al. [43] demonstrated a 7.4% incidence
of therapy-related deaths (the majority of which were due to
pulmonary complications) in the group randomized to HDC
with the same regimen (STAMP I) used at our institution. At
a median follow-up of 37 months, no difference in survival
was observed compared with the control group, even though
the treatment group had fewer occurrences of relapse.
Although only approximately one-third of the predicted
relapses occurred in the HDC arm, the impact of treatment-
related mortality with the BCNU-containing regimen may
preclude the emergence of signiﬁcant survival beneﬁt even
with longer follow-up. Other HDC regimens have not been
associated with PTS and, in the other randomized trials, were
uniformly associated with treatment-related mortality rates
under 2.5%. If future trials assess the principle of dose inten-
siﬁcation in the treatment of breast cancer, these regimens
may very well merit preferential consideration.
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